IP Library Granted Patent US 10,092,657
Granted Patent B2
US 10,092,657 · App. 14/123,624 · Granted Oct 9, 2018

Opsonized β-glucan preparations and methods

Inventors: Nandita Bose (Plymouth, MN); Anissa S. H. Chan (Arden Hills, MN)
Assignee: Biothera, Inc.
A61K47/4823A61K31/716A61K47/61A61K47/64
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,092,657
App. No.
14/123,624
Granted
Oct 9, 2018
Kind
B2
Abstract

Described herein are compositions that include isolated opsonized soluble β-glucan, methods of making those compositions and methods of using those compositions.

Claims (11)

1. A composition consisting of:

isolated opsonized soluble β-(1,6)-[poly-1,3)-D-glucopyranosyl]-poly-β(1,3)-D-glucopyranose β-glucan derived from Saccharomyces cerevisiae able to bind to neutrophils and monocytes.

2. The composition of claim 1 wherein the isolated opsonized soluble β-(1,6)-[poly-1,3)-D-glucopyranosyl]-poly-β(1,3)-D-glucopyranose β-glucan comprises an opsonin coupled to the β(1,6)-[poly-1,3)-D-glucopyranosyl]-poly-β(1,3)-D-glucopyranose.

3. The composition of claim 2 wherein the opsonin is covalently coupled to the β(1,6)-[poly-1,3)-D-glucopyranosyl]-poly-β(1,3)-D-glucopyranose.

4. The composition of claim 3 wherein the opsonin is covalently coupled to the β(1,6)-[poly-1,3)-D-glucopyranosyl]-poly-β(1,3)-D-glucopyranose through a conjugation linker.

5. The composition of claim 2 wherein the opsonin comprises C3, C3a, C3b, iC3b, C3bB, C3bBb, C3d, C3dg, C4, C5, C5a, C5b, C6, C7, C8, C9, or any combination of two or more thereof.

6. A composition consisting of:

isolated iC3b-opsonized soluble β(1,6)-[poly-1,3)-D-glucopyranosyl]-poly-β(1,3)-D-glucopyranose βgulcan derived from Saccharomyces cerevisiae able to bind to neutrophils and monocytes.

7. The composition of claim 6 wherein the iC3b is covalently coupled to the soluble β(1,6)-[poly-1,3)-D-glucopyranosyl]-poly-β(1,3)-D-glucopyranose βgulcan.

8. The composition of claim 7 wherein the iC3b is covalently coupled to the soluble β(1,6)-[poly-1,3)-D-glucopyranosyl]-poly-β(1,3)-D-glucopyranose βgulcan through a conjugation linker.

9. The composition of claim 1 wherein the opsonin is covalently coupled to a plurality of soluble β(1,6)-[poly-1,3)-D-glucopyranosyl]-poly-β(1,3)-D-glucopyranose βglucan molecules.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 18, 2021
From: BIOTHERA, INC.
To: HIBERCELL, INC.
Reel/Frame 054946/0932 →
RELEASE OF SECURITY INTEREST Recorded Apr 2, 2020
From: MIDCAP FINANCIAL SERVICES, LLC
To: BIOTHERA, INC.; LIFE SOURCE BASICS INC.; BIOTHERA HEALTH INC.
Reel/Frame 052297/0045 →
SECURITY INTEREST Recorded Apr 8, 2015
From: BIOTHERA, INC.; LIFE SOURCE BASICS INC.; BIOTHERA HEALTH INC.
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 035361/0929 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 28, 2014
From: BOSE, NANDITA; CHAN, ANISSA S.H.
To: BIOTHERA, INC.
Reel/Frame 032323/0066 →
Continuity (2)
Provisional Application 61493101 · Jun 3, 2011
Related Publication 20140105935A1 · Apr 17, 2014